Non-invasive vagus nerve stimulation for treating alcohol use disorder in veterans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of non-invasive vagus nerve stimulation (nVNS) as a treatment for alcohol use disorder (AUD) in veterans. The research aims to assess the efficacy of nVNS in reducing withdrawal-related distress and cravings, which are significant barriers to recovery. By targeting the vagus nerve, the study seeks to restore physiological balance and improve functional outcomes for veterans suffering from AUD. Participants will receive either active or sham nVNS treatment while their progress is monitored over the course of the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Veterans between 21 and 65 years, any race or ethnicity.
2. Meet current DSM-5 diagnosis of moderate or severe AUD (Structured Clinical Interview for DMS-5 (SCID) interview) with at least one functional disability due to alcohol use, current alcohol craving, and current heavy drinking (\>= 5 drinks (men) / \>= 4 drinks (women) on the same occasion, on 5 or more days in the past month) as defined by the Substance Abuse and Mental Health Services Administration (SAMHSA), and mild to moderate withdrawal symptoms during abstinence.
3. Able to forgo consumption of alcohol for 12-24 hours without any serious discomfort or complications.
4. Capable of complying with study schedule, procedures, and speaks English.
5. Able to provide voluntary written informed consent prior to initiation of visit 1.
6. Able and willing to self-administer nVNS/sham stimulation as instructed for the duration of the study, and willing to commit to the return visit at the end of the study.

Exclusion Criteria:

1. Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar) score \>10 on the day of the scan (symptoms judged to be due to co-existing anxiety or headache disorders will not be counted toward the total).
2. Recent history past 6 months) of severe complications due to alcohol withdrawal (alcohol withdrawal seizures, hallucinations/illusions, delirium tremens).
3. Currently or recently (within last 90 days) enrolled in abstinence-based treatment program.
4. Evidence of a maladaptive pattern of substance use or abuse other than alcohol one month prior to screening visit.
5. Uncontrolled severe psychiatric disorder with psychotic symptoms or cognitive impairment. We will not exclude for PTSD.
6. At risk for suicide requiring urgent higher-level care or homicide (based on the Columbia-Suicide Severity Rating Scale and follow-up clinical interview).
7. History of neurological disorder that might be associated with cognitive dysfunction.
8. History of head trauma involving loss of consciousness \>24 hours
9. Clinically significant uncontrolled/unstable medical illness or clinically significant surgery within 1 month of the screening visit.
10. MRI-related exclusion criteria: cardiac pacemaker, metal fragments in eyes/skin/body, aortic/aneurysm clips, heart-valve replacement, copper intrauterine device, shunt (ventricular or spinal), neuro/bio-stimulators, (for females) pregnant or nursing. Any implants will be reviewed for safety.
11. Vagus nerve stimulation related criteria: active implantable medical device, metallic device implanted at or near the neck, carotid atherosclerosis (narrowing of arteries), cervical vagotomy, clinically significant hypertension, hypotension, bradycardia, or tachycardia, cardiac disease and atherosclerotic cardiovascular disease (severe carotid artery disease (e.g., history of transient ischemic attack (TIA) or stroke), congestive heart failure, severe coronary artery disease or recent myocardial infarction (within 5 years)).
12. Pharmacotherapy for AUD: \>= 2 weeks stability is required to ensure a steady state of medication effects prior to nVNS administration.
13. Currently taking opioids or benzodiazepines.
14. In case it is determined by the investigator during the course of the study, that a subject needs a higher level or care, study participation will be discontinued, and the subject will be excluded from the study.

Where it's running

• VA San Diego Healthcare System, San Diego, CA
  San Diego, California, United States Recruiting

Study contacts

• Principal investigator: Ruth Klaming, PhD — VA San Diego Healthcare System, San Diego, CA
• Study coordinator: Ruth Klaming, PhD
• Email: Ruth.Miller@va.gov
• Phone: (858) 642-3538

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures

  This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.

  Recruiting Université Catholique de Louvain · Brussels, Belgium · NCT07925281

• Thiamine to reduce brain injury in adults with alcohol use disorder

  This trial tests whether thiamine can help protect the brain in adults with moderate to severe alcohol use disorder who drink daily.

  Recruiting Phase 2 Institut National de la Santé Et de la Recherche Médicale, France · Paris, Île-de-France Region · NCT07844720

• Digital Recovery Support for Black adults with Alcohol Use Disorder in Detroit

  This study tests whether a smartphone-based digital recovery program helps Black or African American adults in Detroit maintain their recovery from alcohol use disorder.

  Recruiting Brandeis University · Detroit, Michigan · NCT07724275

• Path180: a computer-based skills program to help teens reduce alcohol use

  This 8-week trial tests Path180, a computer-based skills training, added to usual care for teens 13–19 with alcohol use disorder to see if it improves daily-life coping skills and outcomes.

  Recruiting Brown University · Providence, Rhode Island · NCT07713251

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Psilocybin in Alcohol Use Disorder with Depression (Relapse Prevention)

  This study tests whether higher-dose psilocybin-assisted psychotherapy helps prevent relapse in adults with severe alcohol use disorder and depressive symptoms after detox.

  Recruiting Phase 3 Centre Hospitalier Universitaire de Nīmes · Bayonne and 7 other locations · NCT07638553

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.